NCT03215693View on ClinicalTrials.gov

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

PHASE2UnknownINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

March 9, 2020

Study Completion Date

December 31, 2023

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

X-396 capsule

225mg once daily

Trial Locations (4)

Unknown

Beijing Cancer Hospital, Beijing

Beijing Chest Hospital，Capital Medical University, Beijing

Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences, Beijing

Peking Union College Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY

NCT03215693 - X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | Biotech Hunter | Biotech Hunter